A Study of the Cardiac Effects of ALXN1840 in Healthy Adults
Status:
Enrolling by invitation
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the effect of a supratherapeutic dose of ALXN1840 on the heart rate
(HR)-corrected QT interval (QTc) in healthy adult participants. Moxifloxacin will be used as
the active control.